LATEST STUDY RESULTS:
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing
President and CEO, Canary Cure Therapeutics
Chief Strategy Officer, Co-Founder
Senior Scientific & Medical advisor, Molecular Metabolism
Senior Clinical Development advisor, Obesity & Metabolic Disorder
View DetailsSenior Clinical Development advisor, Obesity & Metabolic Disorder
Senior Scientific Advisor, Obesity & Metabolic Disorders
Legal and Licensing Advisor
Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence New York, NY,...
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing Abstract According to...
CCT-217 Demonstrates Significant Weight Loss and Preserves Lean Body Mass with Potential for Single or Twice-Yearly Dosing New York, November...
Pioneering RNA Therapy
We are revolutionizing healthcare by harnessing the power of cutting-edge RNA therapies to develop and deliver innovative treatments that addresses the root causes of diseases. We are committed to fostering a culture of scientific excellence and collaboration to create life-changing treatments that are safe, effective, and accessible to all.